Founders Financial Alliance LLC Acquires 995 Shares of Pfizer Inc. (NYSE:PFE)

Founders Financial Alliance LLC boosted its holdings in shares of Pfizer Inc. (NYSE:PFE) by 3.6% in the 2nd quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The firm owned 28,419 shares of the biopharmaceutical company’s stock after buying an additional 995 shares during the quarter. Founders Financial Alliance LLC’s holdings in Pfizer were worth $795,000 at the end of the most recent quarter.

Several other large investors also recently added to or reduced their stakes in PFE. 3Chopt Investment Partners LLC lifted its holdings in shares of Pfizer by 97.9% in the second quarter. 3Chopt Investment Partners LLC now owns 22,767 shares of the biopharmaceutical company’s stock worth $637,000 after buying an additional 11,265 shares in the last quarter. Heartland Bank & Trust Co purchased a new position in shares of Pfizer in the second quarter worth $596,000. IMS Capital Management lifted its holdings in shares of Pfizer by 2.0% in the second quarter. IMS Capital Management now owns 104,938 shares of the biopharmaceutical company’s stock worth $3,033,000 after buying an additional 2,029 shares in the last quarter. Brandes Investment Partners LP lifted its holdings in shares of Pfizer by 10.2% in the second quarter. Brandes Investment Partners LP now owns 5,573,282 shares of the biopharmaceutical company’s stock worth $155,871,000 after buying an additional 516,714 shares in the last quarter. Finally, Kimelman & Baird LLC purchased a new position in shares of Pfizer in the second quarter worth $1,313,000. 68.36% of the stock is currently owned by institutional investors.

Pfizer Price Performance

NYSE PFE opened at $28.94 on Tuesday. The company has a market cap of $163.96 billion, a PE ratio of -482.25, a P/E/G ratio of 1.27 and a beta of 0.68. Pfizer Inc. has a 52-week low of $25.20 and a 52-week high of $34.11. The company has a debt-to-equity ratio of 0.65, a quick ratio of 0.60 and a current ratio of 0.86. The firm’s 50 day moving average price is $29.29 and its 200-day moving average price is $28.30.

Pfizer (NYSE:PFE) last announced its quarterly earnings results on Tuesday, July 30th. The biopharmaceutical company reported $0.60 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $0.46 by $0.14. The business had revenue of $13.28 billion for the quarter, compared to the consensus estimate of $12.96 billion. Pfizer had a positive return on equity of 8.42% and a negative net margin of 4.66%. The business’s revenue was up 2.1% compared to the same quarter last year. During the same period last year, the business posted $0.67 EPS. Sell-side analysts forecast that Pfizer Inc. will post 2.66 EPS for the current fiscal year.

Analyst Ratings Changes

A number of equities research analysts recently issued reports on the stock. StockNews.com raised shares of Pfizer from a “hold” rating to a “buy” rating in a research note on Thursday, August 1st. UBS Group upped their price target on shares of Pfizer from $30.00 to $31.00 and gave the company a “neutral” rating in a research note on Wednesday, July 31st. Daiwa America raised shares of Pfizer from a “moderate buy” rating to a “strong-buy” rating in a research note on Wednesday, August 7th. Daiwa Capital Markets raised shares of Pfizer from a “neutral” rating to an “outperform” rating and increased their target price for the company from $28.00 to $34.00 in a research note on Wednesday, August 7th. Finally, Barclays increased their target price on shares of Pfizer from $30.00 to $32.00 and gave the company an “equal weight” rating in a research note on Wednesday, July 31st. Eight investment analysts have rated the stock with a hold rating, seven have assigned a buy rating and one has given a strong buy rating to the company’s stock. Based on data from MarketBeat, the company presently has a consensus rating of “Moderate Buy” and an average target price of $34.54.

About Pfizer

Pfizer Inc discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States, Europe, and internationally. The company offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic, migraine, and women's health under the Eliquis, Nurtec ODT/Vydura, Zavzpret, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands.